Analyzing Intuitive Surgical's Fundamental Performance

By Kim Brooks • Wednesday, December 25 10:10 • Permanent Link

More and more people are talking about Intuitive Surgical over the last few weeks. Is it worth buying the Specialty Industrial Machinery stock at a price of $537.02? Only time will tell. The information below will give you a basic idea of what this investment may entail:

Intuitive Surgical has moved 59.1% over the last year, and the S&P 500 logged a change of 26.3%
ISRG has an average analyst rating of buy and is -3.49% away from its mean target price of $556.42 per share
Its trailing earnings per share (EPS) is $6.23
Intuitive Surgical has a trailing 12 month Price to Earnings (P/E) ratio of 86.2 while the S&P 500 average is 29.3
Its forward earnings per share (EPS) is $7.86 and its forward P/E ratio is 68.3
The company has a Price to Book (P/B) ratio of 12.28 in contrast to the S&P 500's average ratio of 4.74
Intuitive Surgical is part of the Health Care sector, which has an average P/E ratio of 26.07 and an average P/B of 3.53
ISRG has reported YOY quarterly earnings growth of 34.5% and gross profit margins of 0.7%
The company has a free cash flow of $637.52 Million, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. It has a collaboration agreement with FluoGuide A/S for head & neck cancer. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.